How Thrombin-JMI® Works

How Thrombin-JMI^® Works

Thrombin-JMI^® In Practice

Delivery Options for Operating Room Procedures

Delivery Options for Emergency Department Procedures


	The Choice For Thrombin-JMI^® Learn more about the importance of choosing an active and fast-acting¹^,a topical hemostat. View the clinical data More products than ever before for more procedures Now Thrombin-JMI^® offers you more choices in the operating room or emergency department. Learn more about Thrombi-Gel^® (thrombin/gelatin foam hemostat), Thrombi-Pad™ (3x3 hemostatic pad), and the Thrombin-JMI^® Epistaxis Kit

How Thrombin-JMI^® Works

Biologically active for direct clotting

Thrombin-JMI^® is a biologically active hemostatic agent that works directly at the end of the blood coagulation cascade to clot the fibrinogen of the blood directly.^2,3 To see how Thrombin-JMI^® works for bleeding control, play the video.

This MOA animation is produced using Adobe^® Flash^®. To view this animation, you need the free Adobe^® Flash^® plugin.
Adobe^® Flash^® is a registered trademark of Adobe Systems Incorporated.

^a Time for hemostasis is dependent on concentrations of thrombin and fibrinogen.

Thrombin-JMI^® is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible. In various types of surgery, solutions of Thrombin-JMI^® may be used in conjunction with an Absorbable Gelatin Sponge, USP for hemostasis.

Thrombi-Pad™ (3x3 hemostatic pad) is applied topically and is indicated as a trauma dressing for temporary control of moderate to severely bleeding wounds and for the control of surface bleeding from vascular access sites and percutaneous catheters and tubes. Please see the Instructions for Use.

Thrombi-Gel^® (thrombin/gelatin foam hemostat) is applied topically and is indicated as a trauma dressing for temporary control of moderate to severely bleeding wounds and for the control of surface bleeding from vascular access sites and percutaneous catheters and tubes. Please see the Instructions for Use.

Important Safety Information
Because of its action in the clotting mechanism, Thrombin-JMI^® must not be injected or otherwise allowed to enter large blood vessels. Extensive intravascular clotting and even death may result.

Occasionally, the use of topical bovine thrombin preparations has been associated with abnormalities in hemostasis ranging from alterations in prothrombin time (PT) and partial thromboplastin time (PTT) to severe bleeding or thrombosis. These hemostatic effects have rarely been fatal and appear to be related to the formation of cross-reacting bovine antibodies to thrombin and/or factor V. Consultation with an expert in coagulation disorders is recommended if a patient exhibits any of these abnormalities following the use of topical thrombin, particularly following repeat application. Any interventions should consider the immunologic basis of this condition. Patients with antibodies to bovine thrombin preparations should not be re-exposed to these products.

Thrombin-JMI^® should be given to a pregnant woman only if clearly indicated. Safety and effectiveness in children have not been established.

For additional Important Safety Information, please see the full Prescribing Information.

ThrombiGel is a registered trademark of Vascular Solutions, Inc. Thrombin-JMI^® and Thrombi-Pad^™ are trademarks
of King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals^®, Inc.
All other trademarks, registered or unregistered, are the property of their respective owners.

Copyright © 2008, King Pharmaceuticals^®, Inc. All rights reserved. JMI4986 02/2008
Terms of Access | Please read our Privacy Policy for our commitment regarding your personal information.